Quantitative Systematic Strategies LLC Trims Stock Holdings in Horizon Therapeutics Public Limited (NASDAQ:HZNP)

Quantitative Systematic Strategies LLC trimmed its holdings in Horizon Therapeutics Public Limited (NASDAQ:HZNP) by 58.5% in the second quarter, Holdings Channel reports. The institutional investor owned 10,577 shares of the biopharmaceutical company’s stock after selling 14,926 shares during the quarter. Quantitative Systematic Strategies LLC’s holdings in Horizon Therapeutics Public were worth $990,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in Horizon Therapeutics Public by 8.2% in the 1st quarter. BlackRock Inc. now owns 15,377,169 shares of the biopharmaceutical company’s stock valued at $1,415,314,000 after buying an additional 1,170,191 shares in the last quarter. Orbimed Advisors LLC grew its stake in Horizon Therapeutics Public by 4.5% in the 1st quarter. Orbimed Advisors LLC now owns 3,144,355 shares of the biopharmaceutical company’s stock valued at $289,406,000 after buying an additional 135,600 shares in the last quarter. Ameriprise Financial Inc. grew its stake in Horizon Therapeutics Public by 88.7% in the 1st quarter. Ameriprise Financial Inc. now owns 2,730,327 shares of the biopharmaceutical company’s stock valued at $251,777,000 after buying an additional 1,283,244 shares in the last quarter. Geode Capital Management LLC grew its stake in Horizon Therapeutics Public by 3.4% in the 1st quarter. Geode Capital Management LLC now owns 2,705,039 shares of the biopharmaceutical company’s stock valued at $248,636,000 after buying an additional 89,414 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in shares of Horizon Therapeutics Public by 4.4% during the 1st quarter. Franklin Resources Inc. now owns 2,100,928 shares of the biopharmaceutical company’s stock valued at $193,369,000 after purchasing an additional 89,493 shares in the last quarter. Institutional investors and hedge funds own 87.90% of the company’s stock.

In other news, Director Michael G. Grey sold 5,000 shares of the company’s stock in a transaction dated Thursday, July 22nd. The shares were sold at an average price of $100.04, for a total transaction of $500,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Timothy P. Walbert sold 25,000 shares of the company’s stock in a transaction dated Friday, July 30th. The shares were sold at an average price of $101.74, for a total transaction of $2,543,500.00. The disclosure for this sale can be found here. Insiders sold 124,011 shares of company stock valued at $12,635,840 over the last three months. 3.20% of the stock is currently owned by insiders.

Horizon Therapeutics Public stock traded down $1.81 during mid-day trading on Monday, hitting $107.90. The company’s stock had a trading volume of 17,079 shares, compared to its average volume of 1,590,159. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.55 and a quick ratio of 2.25. The stock has a market cap of $24.37 billion, a price-to-earnings ratio of 47.94, a price-to-earnings-growth ratio of 1.56 and a beta of 1.08. The business has a 50 day moving average price of $104.00 and a 200-day moving average price of $95.78. Horizon Therapeutics Public Limited has a 12 month low of $66.41 and a 12 month high of $111.70.

Horizon Therapeutics Public (NASDAQ:HZNP) last posted its quarterly earnings results on Tuesday, August 3rd. The biopharmaceutical company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $0.87 by $0.75. The business had revenue of $832.55 million during the quarter, compared to the consensus estimate of $697.69 million. Horizon Therapeutics Public had a net margin of 20.27% and a return on equity of 27.41%. The firm’s revenue for the quarter was up 79.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.40 earnings per share. On average, equities research analysts expect that Horizon Therapeutics Public Limited will post 4.35 earnings per share for the current fiscal year.

A number of research firms have recently commented on HZNP. BMO Capital Markets boosted their price target on shares of Horizon Therapeutics Public from $118.00 to $132.00 and gave the company an “outperform” rating in a research report on Thursday, August 5th. Citigroup boosted their price target on shares of Horizon Therapeutics Public from $117.00 to $121.00 and gave the company a “buy” rating in a research report on Thursday, August 5th. Zacks Investment Research upgraded shares of Horizon Therapeutics Public from a “sell” rating to a “hold” rating and set a $108.00 price target for the company in a research report on Thursday, July 29th. The Goldman Sachs Group boosted their price target on shares of Horizon Therapeutics Public from $96.00 to $107.00 and gave the company a “neutral” rating in a research report on Tuesday, August 24th. Finally, Morgan Stanley lifted their price objective on shares of Horizon Therapeutics Public from $103.00 to $135.00 and gave the stock an “overweight” rating in a report on Thursday, August 26th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Horizon Therapeutics Public presently has a consensus rating of “Buy” and an average price target of $117.73.

About Horizon Therapeutics Public

Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.

Further Reading: Growth and Income Funds

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics Public Limited (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.